RJK-RT2831

N/A

Report date: 2026/01/15 10:57:35

Base Information

Drug NameRJK-RT2831

Drug Alias Namea humanized IgG1 bispecific antibody targeting CD33 and CD123RJK-RT2831RJKRT2831RT-2831RT2831

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-CD123Anti-Myeloid cell surface antigen CD33

TargetsInterleukin-3 receptor subunit alphaMyeloid cell surface antigen CD33

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesNanjing RegeneCore Biotech Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing RegeneCore Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A